Why Is The Hijacking Of A Human Erythrocyte Signalling Pathway Essential For Malaria Infection?
Funder
National Health and Medical Research Council
Funding Amount
$510,890.00
Summary
Malaria drug resistance is spreading and the world needs cost-effective new drugs. We found 2 human enzymes, known targets of cancer chemotherapy, to be key for parasite survival in red blood cells. We aim to understand why these human proteins are crucial for the parasite and to identify new human proteins hijacked by malaria. This will open exciting options for antimalarial drug discovery: to harness funds invested in cancer drugs by targeting proteins with dual roles in cancer and malaria.
Suppression Of Immunity By The Malaria Parasite Antigen Plasmodium Falciparum Erythrocyte Membrane Protein-1 (PfEMP-1)
Funder
National Health and Medical Research Council
Funding Amount
$96,698.00
Summary
The malaria parasite P. falciparum infects red blood cells and makes the cells put on their surface a protein called PfEMP-1. The parasite can effectively “hide” by constantly changing this protein and making it unrecognizable by the immune system. PfEMP-1 can also suppress the immune system so that it can’t respond adequately to infection. Therefore, understanding PfEMP-1 function is important. I will investigate how PfEMP-1 can do this by looking at its cross talk with the immune system.
Characterization Of A Novel IFNbeta Signaling Axis Mediated Via IFNAR1
Funder
National Health and Medical Research Council
Funding Amount
$353,754.00
Summary
Type I interferons (IFNs) play an important role in regulating immune responses to pathogens and tumors and are used therapeutically. This project will investigate a novel IFN signaling axis that we have recently characterized that is mediated via the low affinity IFN receptor, IFNAR1. This signaling axis occurs independently of the high affinity IFN receptor IFNAR2 and contributes to lethality in a model of septic shock.